Associated Papers
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.
Li X et al.
Journal of Cancer Research and Clinical Oncology, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_5_suppst5.xlsx › table_uff
Molecular Insights on the Conformational Transitions and Activity Regulation of the c-Met Kinase Induced by Ligand Binding.
Liu Z et al.
Journal of Chemical Information and Modeling, 2023
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T et al.
Journal of Hematology & Oncology, 2022
A rapid and durable response to cabozantinib in an osimertinib-resistant lung cancer patient with MET D1228N mutation: a case report.
Kuang Y et al.
Annals of Translational Medicine, 2021
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Wang Y et al.
Lung Cancer (amsterdam, Netherlands), 2020
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA et al.
Lung Cancer (amsterdam, Netherlands), 2020
Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors.
Shen B et al.
Future Oncology (london, England), 2019
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.
Kang J et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2018
Select a paper to view details